Benchmark analyst Bill Sutherland downgraded Amedisys to Hold from Buy, noting that the stock has risen 36% since the company announced its now-closed deal to acquire Compassionate Care Hospice and a strong Q3 earnings report. Amedisys now sells at “a wide premium” to other home health/hospice names and Sutherland recommends investors await a better entry point, as he also thinks there is modest integration risk for Compassionate.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.